New insights into diuretic use in patients with chronic renal disease

Journal of the American Society of Nephrology

Volumn 13, Issue 3, 2002, Pages 798-805

  Wilcox, Christopher S ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANION; CALCIUM ANTAGONIST; CARBONATE DEHYDRATASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; SODIUM ION;

ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY DISEASE; DIURESIS; DOSE RESPONSE; DRUG BINDING; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG METABOLISM; HUMAN; INHIBITION KINETICS; KIDNEY PROXIMAL TUBULE; NEPHRON; NEPHROTIC SYNDROME; OTOTOXICITY; PRIORITY JOURNAL; SODIUM ABSORPTION;

EID: 0036191529     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Codependence of renal calcium and sodium transport
2. The organic anion transporter family: From physiology to ontogeny and the clinic
3. Response of deep nephrons and the terminal collecting duct to a reduction in renal mass
4. High dosage metolazone in chronic renal failure
5. The use of diuretics in varying degrees of renal impairment: An overview
6. Response of the kidney to furosemide: I, Importance of salt intake and renal compensation
7. Salt sensitivity of blood pressure in chronic renal failure: Evidence for renal control of body fluid distribution in man
8. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia
9. Disposition and response to bumetanide and furosemide
10. Clinical pharmacology of torasemide, a new loop diuretic
11. Torsemide: A pyridine-sulfonylurea loop diuretic
12. Torasemide: An update of its pharmacological properties and therapeutic efficacy
13. Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver
14. Clinical pharmacology of loop diuretics and their use in chronic renal insufficiency
15. Role of the kidneys in the metabolism of furosemide: Its inhibition by probenecid
16. Insights into ototoxicity. Analogies to nephrotoxicity
17. Depression of renal clearance of furosemide in man by azotemia
18. Expression cloning and characterization of a novel multispecific organic anion transporter
19. Interaction and transport of thizide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1
20. Voltage-driven p-aminohippurate, chloride, and urate transport in porcine renal brush-border membrane vesicles
21. + depletion
22. Mild metabolic alkalosis impairs the natriuretic response to bumetanide in normal human subjects
23. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome
24. Mechanisms and management of nephrotic edema
25. Facilitation by serum albumin of renal tubular secretion of organic ions
26. 35S]furosemide and its depression by albumin binding
27. The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit
28. Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit
29. Intratubular albumin blunts the response to furosemide - A mechanism for diuretic resistance in the nephrotic syndrome
30. Disorders of body fluids, sodium and potassium in chronic renal failure
31. + channels are regulated by flow
32. Diuretic resistance
33. Loop diuretics for chronic renal insufficiency: A continuous infusion is more efficacious than bolus therapy
34. The effects of fenoldopam, a selective dopamine receptor agonist on systemic and renal hemodynamics in normotensive subjects
35. Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: Ineffective and probably dangerous
36. Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure
37. 1 receptor antagonist
38. BG9719 (CVT-124), an A1-adenosine receptor antagonist, protects against the decline in renal function observed with heart failure therapy
39. Anti-aldosteronergic effect of torasemide
40. A volume-independent component to post-diuretic sodium retention in man
41. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients
42. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis
43. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients
44. Coadministration of albumin and furosemide in patients with the nephrotic syndrome
45. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome
46. The time course of delivery of furosemide into urine; an independent determinant of overall response
47. Does it make sense to administer albumin to the patient with nephrotic oedema?
48. Diuretic effect of frusemide in patients with nephrotic syndrome: Is it potentiated by intravenous albumin?